Alector, a Phase 1 biotech developing therapies for neurodegeneration, filed on Monday with the SEC to raise up to $150 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2013 and booked $22 million in collaboration and grant revenue for the 12 months ended September 30, 2018. It plans to list on the Nasdaq under the symbol ALEC. Alector filed confidentially on October 12, 2018. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
